Boston Medical Sciences' AIM4CRC Designated as U.S. FDA Breakthrough Device ~Accelerating Commercialization in the U.S. Market and Global Expansion with Stool-Free Virtual Colonoscopy™ AI Technology~
NQ Score
0/100
N1 Content Completeness
4
Key facts
- Boston Medical Sciences' AIM4CRC Designated as U.S. FDA Breakthrough Device ~Accelerating Commercialization in the U.S. Market and Global Expansion with Stool-Free Virtual Colonoscopy™ AI Technology~
- Boston Medical Sciences' AI-powered "stool-free virtual colonoscopy™ examination system AIM4CRC" has been designated as a Breakthrough Device by the U.S. FDA. This will reduce patient burden in colorectal cancer screening and accelerate its commercialization in the US market.
- Source: PR TIMES
- Date: Thu May 14 2026 18:00:02 GMT+0900 (Japan Standard Time)
Direct answer
Boston Medical Sciences' AI-powered "stool-free virtual colonoscopy™ examination system AIM4CRC" has been designated as a Breakthrough Device by the U.S. FDA. This will reduce patient burden in colorectal cancer screening and accelerate its commercialization in the US market.
- Citation
- Boston Medical Sciences' AIM4CRC Designated as U.S. FDA Breakthrough Device ~Accelerating Commercialization in the U.S. Market and Global Expansion with Stool-Free Virtual Colonoscopy™ AI Technology~ (Thu May 14 2026 18:00:02 GMT+0900 (Japan Standard Time)), PR TIMES
- Source
- PR TIMES
- Date
- Thu May 14 2026 18:00:02 GMT+0900 (Japan Standard Time)
AI Summary (NQ-processed)
Boston Medical Sciences' AI-powered "stool-free virtual colonoscopy™ examination system AIM4CRC" has been designated as a Breakthrough Device by the U.S. FDA. This will reduce patient burden in colorectal cancer screening and accelerate its commercialization in the US market.
AI Analysis
Frequently Asked Questions
- Q: What are the key facts in this article?
- A: Boston Medical Sciences' AI-powered "stool-free virtual colonoscopy™ examination system AIM4CRC" has been designated as a Breakthrough Device by the U.S. FDA. This will reduce patient burden in colorectal cancer screening and accelerate its commercialization in the US market.
- Q: What is the direct answer?
- A: Boston Medical Sciences' AI-powered "stool-free virtual colonoscopy™ examination system AIM4CRC" has been designated as a Breakthrough Device by the U.S. FDA. This will reduce patient burden in colorectal cancer screening and accelerate its commercialization in the US market.
- Q: What is the source and date?
- A: Source: https://prtimes.jp/main/html/rd/p/000000008.000129637.html | Date: Thu May 14 2026 18:00:02 GMT+0900 (Japan Standard Time)